<div id="readability-page-1"><p>Sei Investments Co. trimmed its stake in shares of  Hologic, Inc. (NASDAQ:HOLX - Free Report) by 7.9% in the 2nd quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 1,379,476 shares of the medical equipment provider's stock after selling 118,671 shares during the period. Sei Investments Co. owned approximately 0.62% of Hologic worth $89,887,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p><ul><li>Time to buy these 3 healthcare companies that raised revenue guidance?</li></ul><p>Several other institutional investors and hedge funds also recently added to or reduced their stakes in HOLX. Invesco Ltd. grew its position in  Hologic by 72.5% in the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider's stock worth $543,486,000 after purchasing an additional 3,505,828 shares during the period.  Norges Bank purchased a new position in shares of  Hologic in the 2nd quarter worth $180,055,000.  Allspring Global Investments Holdings LLC grew its holdings in shares of  Hologic by 473.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider's stock worth $111,180,000 after acquiring an additional 1,405,085 shares during the period.  Black Creek Investment Management Inc. increased its position in  Hologic by 26.1% during the second quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider's stock valued at $262,453,000 after acquiring an additional 832,444 shares during the last quarter.  Finally, Arrowstreet Capital Limited Partnership lifted its holdings in  Hologic by 28.1% in the second quarter. Arrowstreet Capital Limited Partnership now owns 2,767,813 shares of the medical equipment provider's stock valued at $180,351,000 after acquiring an additional 606,782 shares during the period. Hedge funds and other institutional investors own  94.73% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>A number of research firms have issued reports on HOLX. Stephens downgraded Hologic from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and cut their price target for the company from $78.00 to $76.00 in a research note on Wednesday, October 22nd. Morgan Stanley lifted their price objective on Hologic from $69.00 to $76.00 and gave the company an &#34;equal weight&#34; rating in a research report on Tuesday, November 11th. BTIG Research  reiterated a &#34;neutral&#34; rating on shares of Hologic in a research note on Tuesday, October 21st. Weiss Ratings  reaffirmed a &#34;hold (c)&#34; rating on shares of Hologic in a report on Friday, October 31st. Finally, Evercore ISI  set a $78.00 target price on Hologic and gave the stock an &#34;outperform&#34; rating in a report on Tuesday, October 7th. Five analysts have rated the stock with a Buy rating and fourteen have issued  a Hold rating to the stock. According to MarketBeat.com, Hologic presently has a consensus rating of &#34;Hold&#34; and an average target price of $79.29.</p><ul><li>Can Butterfly Network Spread its Wings in 2023?</li></ul><p><b>Check Out Our Latest Analysis on Hologic</b></p><h2>Insiders Place Their Bets</h2><p>In other news, CEO Stephen P. Macmillan sold 138,358 shares of the firm's stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Christiana Stamoulis sold 7,402 shares of the firm's stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the transaction, the director directly owned 47,336 shares in the company, valued at $3,458,841.52. This trade represents a 13.52% decrease in their position. The SEC filing for this sale provides additional information. 1.88% of the stock is currently owned by corporate insiders. </p><h2>Hologic Price Performance</h2><p>HOLX opened at $74.83 on Friday. The stock has a market cap of $16.68 billion, a P/E ratio of 30.17, a PEG ratio of 2.12 and a beta of 0.70. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $76.29. The company has a quick ratio of 3.06, a current ratio of 3.75 and a debt-to-equity ratio of 0.50. The business has a fifty day moving average of $72.88 and a 200 day moving average of $68.15. </p><p>Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, topping the consensus estimate of $1.10 by $0.03. The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.03 billion. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The firm's revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.01 EPS.  As a group, sell-side analysts anticipate that  Hologic, Inc. will post 4.28 EPS for the current year. </p><h2>Hologic Profile</h2> (Free Report)<p>Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Hologic</li><li>The Role Economic Reports Play in a Successful Investment Strategy</li><li>3 Recently Downgraded Stocks to Avoid in 2026</li><li>How to Calculate Options Profits</li><li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li><li>Profitably Trade Stocks at 52-Week Highs</li><li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SE9MWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SE9MWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Hologic Right Now?</h2><p>Before you consider Hologic, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.</p><p>While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

HOLX

SEIC

<p>Sei Investments Co. reduced its stake in Hologic, Inc. by 7.9% in Q2, owning 1,379,476 shares worth $89.9M. Other investors adjusted their positions, with Invesco Ltd. increasing its stake by 72.5%. Analysts issued mixed ratings, with a consensus "Hold" and average target price of $79.29. CEO Stephen Macmillan sold 138,358 shares, decreasing his ownership by 10.08%. Hologic's stock opened at $74.83, with a market cap of $16.68B and a 52-week high of $76.29.</p>

Sei Investments Co. Reduces Stock Position in Hologic, Inc. $HOLX